Oculis (NASDAQ:OCS) Given "Buy" Rating at Chardan Capital

Oculis (NASDAQ:OCS - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $28.00 price objective on the stock. Chardan Capital's price target would suggest a potential upside of 48.62% from the stock's current price.

Separately, HC Wainwright lowered their price objective on shares of Oculis from $30.00 to $29.00 and set a "buy" rating for the company in a research report on Thursday.

Oculis Trading Up 2.4 %

NASDAQ OCS opened at $18.84 on Thursday. The company has a market capitalization of $763.10 million, a PE ratio of -9.76 and a beta of 0.02. Oculis has a 12 month low of $10.55 and a 12 month high of $23.08. The stock has a 50-day simple moving average of $20.82 and a 200 day simple moving average of $16.86. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. Research analysts forecast that Oculis will post -2.09 EPS for the current year.

Institutional Trading of Oculis

A number of large investors have recently bought and sold shares of the business. abrdn plc boosted its holdings in shares of Oculis by 23.0% in the fourth quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after buying an additional 188,871 shares during the period. Geode Capital Management LLC boosted its stake in Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares during the period. XTX Topco Ltd bought a new position in Oculis during the 4th quarter worth about $225,000. Bellevue Group AG acquired a new stake in shares of Oculis in the 4th quarter valued at about $170,000. Finally, Bank of America Corp DE lifted its holdings in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after purchasing an additional 10,667 shares in the last quarter. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads